Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3092-3096

  Frankenburg, Shoshana ^a   Glick, Dvora ^b   Klaus, Sidney ^a   Barenholz, Yechezkel ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TOPICAL DRUG ADMINISTRATION;

EID: 0031728936     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3092     Document Type: Article

References (24)

1. Aerdts, S. J., R. van-Dalen, H. A. Clasener, J. Festen, H. J. van-Lier, and E. J. Vollaard. 1991. Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A prospective, blinded, randomized trial of the effect of a novel regimen. Chest 100:783-791.
2. Ashford, R. W., P. Desjeux, and P. deRaadt. 1992. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol. Today 8:104-105.
3. Barenholz, Y., and R. Cohen. 1995. Rational design of amphiphile-based drug carriers and sterically stabilized carriers. J. Liposome Res. 5:905-932.
4. Bensalah, A., H. Zakraoui, A. Zaatour, A. Ftaiti, B. Zaafouri, A. Garraoui, P. L. Olliaro, K. Dellagi, and R. Benismail. 1995. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am. J. Trop. Med. Hyg. 53:162-166.
5. Bent, J. P. III, and F. A. Kuhn. 1996. Antifungal activity against allergic fungal sinusitis organisms. Laryngoscope 106:1331-1334.
6. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of amphotericin B. J. Clin. Microbiol. Rev. 9:512-531.
7. Cohen, R., I. Polacheck, S. Benita, M. Levi, and Y. Barenholz. 1996. Comparative evaluation of five types of amphiphile-based assemblies containing amphotericin B. In Program and abstracts of the Conference on Liposome Advances: Progress in Drug Delivery and Vaccine Delivery. Centre for Drug Delivery Research, School of Pharmacy, University of London, London, United Kingdom.
8. Dimartino, L., R. N. Davidson, R. Giacchino, S. Scotti, F. Raimondi, E. Casstagnola, L. Tasso, A. Cascio, L. Gradoni, M. Gramiccia, M. Pettoellomantovani, and A. D. M. Bryceson. 1997. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J. Pediatr. 131:271-277.
9. El-On, J., J. P. Geoffrey, E. Witztum, and C. L. Greenblatt. 1984. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob. Agents Chemother. 26:745-751.
10. El-On, J., L. Weinrauch, R. Livshin, Z. Even Paz, and G. P. Jacobs. 1985. Topical treatment of recurrent cutaneous leishmaniasis with ointment containing paromomycin and methyl-benzethonium chloride. Br. Med. J. 291: 704.
11. Engelhard, D., A. Eldor, I. Polacheck, I. Hardan, D. Ben-Yehuda, S. Amselem, I. F. Salkin, G. Lopez-Berestein, T. Sacks, E. A. Rachmilewitz, and Y. Barenholz. 1993. Disseminated fusariosis treated with amphotericin B-phospholipid complex. Leuk. Lymphoma 9:385-392.
12. Gangneux, J. P., A. Sulahian, Y. J. F. Garin, and F. Derouin. 1996. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans. R. Soc. Trop. Med. Hyg. 90:574-577.
13. Giri, O. P. 1993. Amphotericin B therapy in kala-azar J. Indian Med. Assoc. 91:91-93.
14. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 2:S133-S144.
15. Klaus, S., O. Axelrod, F. Jonas, and S. Frankenburg. 1994. Changing patterns of cutaneous leishmaniasis in Israel. Trans. R. Soc. Trop. Med. Hyg. 88:649-650.
16. Lasic, D. D. 1992. Mixed micelles in drug delivery. Nature 355:279-280.
17. Llanos-Cuentas, A., J. Echevarria, J. Chang, P. Campos, J. Cieza, D. Lentnek, D. Gonzalez, M. Robbins, and R. Williams. 1991. Randomized trial of amphotericin B complex (ABLC) versus Fungizone in patients with mucocutaneous leishmaniasis. Mem. Inst. Oswaldo Cruz 86(Suppl.):238.
18. Lotery, A. J., J. R. Kerr, and B. A. Page. 1994. Fungal keratitis caused by Scopulariopsis brevicaulis: successful treatment with topical amphotericin B and chloramphenicol without the need for surgical debridement. Br. J. Ophthalmol. 78:730.
19. Neva, F. A., C. Ponce, E. Ponce, R. Kreutzer, F. Modabber, and P. Olliaro. 1997. Non ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin. Trans. R. Soc. Trop. Med. Hyg. 91:473-475.
20. Panosian, C. B., M. Barza, F. Szoka, and D. J. Wyler. 1984. Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 25:655-656.
21. Paul, M., R. Durand, H. Fessi, D. Rivollet, R. Houin, A. Astier, and M. Deniau. 1997. Activity of a new liposomal formulation of amphotericin B against two strains of leishmania infantum in a murine model. Antimicrob. Agents Chemother. 41:1731-1734.
22. Pleyer, U., A. Legmann, B. J. Mondino, and D. A. Lee. 1992. Use of collagen shields containing amphotericin B in the treatment of experimental Candida albicans-induced keratomycosis in rabbits. Am. J. Ophthalmol. 113:303-308.
23. Vierl, U., L. Lobbecke, N. Nagel, and G. Cevc. 1994. Solute effects on the colloidal and phase behavior of lipid bilayer membranes: ethanol-dipalmitoylphosphatidylcholine mixtures. Biophys. J. 67:1067-1079.
24. Yardley, V., and S. Croft. 1997. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob. Agents Chemother. 41: 752-756.